We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Novo Nordisk A/S
Health Care · Pharmaceuticals
Pure-play on the GLP-1 obesity TAM with the deepest dataset in the class. Ozempic + Wegovy combined run-rate sits near $40B; SELECT cardiovascular outcomes trial unlocked broad payer coverage and Medicare Part D access for cardio-risk reduction.
Pipeline anchors on CagriSema (cagrilintide + semaglutide) and oral semaglutide reformulations, both targeting next-gen efficacy parity with $LLY tirzepatide/retatrutide.
- Installed prescriber base + 10+ years of real-world semaglutide safety data
- Kalundborg + Clayton (NC) capacity expansions to relieve supply-constrained Wegovy demand
- Foundation ownership = long-duration capital allocation, no LBO/activist overhang
- Oral semaglutide opens the non-injectable obesity market
- Cardio + renal + MASH label extensions widen reimbursable population
- $LLY Zepbound out-trials Wegovy on weight-loss magnitude in head-to-head SURMOUNT data; share donor risk
- CagriSema Phase 3 readout (REDEFINE) missed buyside efficacy bar - stock repriced -20%+ on the print
- US compounding pharmacy GLP-1 supply has eroded brand pricing; FDA shortage delisting only partial relief
- Patent cliff on semaglutide ~2031-2032 in major markets, biosimilar/generic risk
No key levels recorded for this ticker.